Chronic graft-versus-host disease (GVHD) can be associated with significant morbidity, in
part because of nonreversible fibrosis, which impacts physical functioning (eye, skin, lung …

Abstract Treatment of chronic graft-versus-host disease is intended to produce a sustainable
benefit by reducing symptom burden, controlling objective manifestations of disease activity …

Positive results from recent clinical trials have significantly expanded current therapeutic
options for patients with chronic graft-versus-host disease (GVHD). However, new insights …

Recognition of the earliest signs and symptoms of chronic graft-versus-host disease (GVHD)
that lead to severe manifestations remains a challenge. The standardization provided by the …

Abstract The 2006 National Institutes of Health (NIH) Consensus paper presented
recommendations by the Ancillary Therapy and Supportive Care Working Group to support …

The complexity of chronic graft-versus-host disease (GVHD) and the lack of established
research methods have made it difficult to design, conduct, and analyze clinical trials …

The lack of standardized criteria for quantitative measurement of therapeutic response in
clinical trials poses a major obstacle for the development of new agents in chronic graft …

Biology-based markers that can be used to confirm the diagnosis of chronic graft-versus-
host disease (GVHD) or monitor progression of the disease could help in the evaluation of …

Abstract In 2005, the National Institutes of Health (NIH) Chronic Graft-versus-Host Disease
(GVHD) Consensus Response Criteria Working Group recommended several measures to …

Abstract The 2005 National Institutes of Health (NIH) Consensus Conference proposed new
criteria for diagnosing and scoring the severity of chronic graft-versus-host disease (GVHD) …